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ABSTRACT: Background. Surgical resection represents the gold stand-
ard for the treatment of sinonasal malignancies. This study reviewed the
published outcomes on endoscopic surgery or endoscopic-assisted sur-
gery versus open approach for the management of sinonasal
adenocarcinomas.
Methods. PubMed, EMBASE, the Cochrane Library, and CENTRAL elec-
tronic databases were searched for English language articles on endo-
scopic surgery, endoscopic-assisted surgery, and open approach for
sinonasal adenocarcinomas. Each article was examined for patient data
and outcomes for analysis.
Results. Thirty-nine articles including 1826 patients were used for the
analysis. The endoscopic surgery and endoscopic-assisted surgery
showed low rates of major complications (6.6% and 25.9%, respec-
tively) compared to open approaches (36.4%; p < .01). The incidence
of local failure was lower in the endoscopic surgery group as com-
pared with open approach patients (17.8% vs 38.5%; p < .01,
respectively). The multivariate Cox regression model showed a worst
overall survival related to advanced T classification and open
approach.
Conclusion. From the existing body of data, there is growing evidence
that endoscopic nasal resection is a safe surgical option in the manage-
ment of sinonasal adenocarcinomas. VC 2015 Wiley Periodicals, Head
Neck 38: E2267–E2274, 2016
KEY WORDS: adenocarcinoma, endoscopy, paranasal sinus, postop-
erative complications, patient outcome assessment
INTRODUCTION
Sinonasal malignancies pose a diagnostic and therapeutic
challenge because of their location, resulting symptoms,
and presentation mimicking benign lesions.1 The inci-
dence of nasal and paranasal cancers in most relevant
series is less than 1 per 100,000 per year. The ethmoid
sinuses are mostly involved (between 5% and 30%), and
adenocarcinoma is the most frequent malignancy of the
ethmoid sinuses.2 Primary adenocarcinomas of the sino-
nasal tract are a diverse group of malignancies that can
be initially classified as salivary (5% to 10%) and nonsa-
livary types.3 The World Health Organization classifica-
tion of nonsalivary gland type sinonasal adenocarcinomas
considers the categories: high-grade and low-grade adeno-
carcinomas of nonintestinal type and intestinal-type ade-
nocarcinoma (ITAC) of colonic and mucinous subtypes.4
Because symptoms are usually similar to inflammatory
sinusitis, the diagnosis may be delayed and tumors are
diagnosed at advanced stages. As with other malignancies,
the presence of unilateral symptoms, typically obstruction,
rhinorrhea, and epistaxis, should serve as a warning sign for
the clinician. Men are affected 2 to 6 times more often than
women, reflecting occupational factors. In most series, the
cohorts are relatively small and often no distinction is made
among the several subtypes of adenocarcinomas.5 Surgical
resection with negative margins, followed by adjuvant
radiotherapy for advanced lesions, represents the gold
standard for the management of sinonasal adenocarcino-
mas. Inability to control local disease is recognized as the
cause of death in sinonasal malignancies, highlighting the
importance of complete surgical resection at the primary
site.6 In this light, numerous open surgical approaches were
used to deal with the complex anatomy of the paranasal
sinuses and adjacent structures. Although traditional surgi-
cal management is successful in yielding 5-year survival
rates ranging from 40% to 70%, open approaches carry spe-
cific complications, functional, and cosmetic risks, even
with proper execution.7–9 Recently, endoscopic techniques
gained popularity in the management of benign and malig-
nant sinonasal tumors. However, endoscopic management
of malignant neoplasms, such as sinonasal adenocarcinoma,
is still under evaluation.5 Evidence-based guidelines on this
topic are lacking because of the absence of randomized
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control trials, the low incidence of sinus adenocarcinoma
that renders prospective studies difficult, and because of the
widely variable reporting methods used with data from var-
ious histopathological types often aggregated together.
Consequently, the purpose of this study was to compile and
analyze outcome data in patients who received surgical
treatment (endoscopic or open surgery) for sinonasal ade-
nocarcinoma taking into account the variety of reporting
methods for outcomes and tumor characteristics found
across the literature on this entity.
MATERIALS AND METHODS
Literature search protocol
A comprehensive review of the English language litera-
ture on the surgical management of sinonasal adenocarci-
nomas was performed using PubMed, EMBASE, the
Cochrane Library, and CENTRAL electronic databases
(see Figure 1). Three searches using the keywords (1) sur-
gery OR endoscopic OR craniofacial OR open approach,
(2) adenocarcinoma OR malignancy OR tumor, and (3)
paranasal OR sinonasal OR nasal were performed. These
searches were combined with the AND function to find all
relevant articles. The following inclusion criteria were
applied to each article: (1) available information on out-
come data with survival statistics related to the treatment
of sinonasal or skull base adenocarcinomas, and (2) data
concerning the type of surgical resection: endoscopic, or
endoscopic assisted, or open approaches/craniofacial resec-
tion.7,9–46 When multiple articles were published by a sin-
gle institution8,47–49 with updated follow-up on their
patient populations, the most recent publication was used
for analysis to maximize accuracy of follow-up data and
reduce the risk of redundancy.9,35,41 Articles not meeting
the inclusion criteria were excluded. Further exclusion cri-
teria were: case reports without significant outcome data,50
reports on surgical debulking, and studies regarding local
5-fluorouracil applications.51–54 To further reduce the risk
of an incomplete literature search, a manual search through
the references of the included articles was performed.
Analysis protocol
Data from the studies were first extracted and assessed
by the principal investigator (M.G.) and thereafter inde-
pendently by 2 coauthors (D.A. and G.C.) using standar-
dized data forms. Articles were examined for data
resolution with the intent to perform a meta-analysis. Dif-
ferent methods of meta-analyses were considered in
reviewing the literature to seek results that would provide
meaningful analysis with the least risk of introducing
biases. The quality assessment of diagnostic accuracy stud-
ies (QUADAS-2) tool was used to evaluate relevant study
design characteristics of the included articles.55 A graphical
display of QUADAS-2 results is shown in Figure 2. Based
on the surgical treatment, 3 groups were defined: endo-
scopic surgery, endoscopic-assisted surgery, and open
approach. The articles were analyzed to extrapolate all
information for each treated patient about age, sex, occupa-
tional exposure, smoking, tumor staging, total admission
time, adjuvant therapies, disease-free survival (in months),
events of local recurrence, regional recurrence, distant
metastasis, total follow-up time (in months), and survival.
However, survival data were limited in the endoscopic-
assisted surgery group; thus, we compared only survival
data from endoscopic surgery and open approach groups.
The articles were also reviewed for data concerning the
occurrence of perioperative and postoperative complica-
tions. A major complication was defined as at least one
reported event of: cerebrospinal fluid leak, hemorrhage or
severe epistaxis, stroke, severe pneumocephalus, meningi-
tis, brain abscess, sepsis, or postoperative death. A minor
complication was noted as at least one reported event of:
light or moderate epistaxis, light or moderate pneumoce-
phalus, agitation, minor subdural blood collection, central
FIGURE 1. Flowchart of study selection.
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venous catheter infection, fever, deep venous thrombosis,
epilepsy, headache, pneumonia, hallucinations, cranial
nerve palsy, anisocoria, diplopia, or epiphora.
Statistical analysis
To test the differences among groups, the Fisher’s exact
test was used for categorical data, whereas the t test was
used for continuous data. The role of each possible prog-
nostic factor (univariate analysis) and their independent
effect (multivariate analysis) was explored using logistic
regression model or Cox proportional hazard model, as
appropriate. Unfortunately, because of discrepancies in
the presentation of survival data, including follow-up, it
was impossible to calculate Kaplan–Meier curves. Proba-
bility values lower than .05 were considered statistically
significant. All analyses were performed with STATA
12.0 software (Stata, College Station, TX).
RESULTS
The search was performed in October 2014 and yielded
1360 articles, of which 39 articles met inclusion’s crite-
ria,7,9–46 comprising a total result of 1826 patients for ini-
tial analysis. Thirty-six studies7,9–14,16–20,22,23,25–46 with
1404 cases included at least 3 years of follow-up and
were included in the final analysis. All series were retro-
spective. Most series presented outcome data from hetero-
geneous histologies,7,9,14–17,20–22,25–27,31,32,34,37–39,43 at
differing stages, of patients who received a variety of
treatment strategies over a relatively long timeframe. The
largest series of ethmoid adenocarcinomas was published
by the French GETTEC group.30 Table 1 summarizes the
extrapolated data from each included study. Palliative
treatment was administered in 94 patients (5.1%), 431
patients (23.6%) received endoscopic surgery, 31 patients
(1.7%) received endoscopic-assisted surgery, and 1270
patients (69.6%) underwent an open approach. Table 2
shows the patients’ characteristics among surgical groups.
In 2002 (with implementation starting from 2003), the
American Joint Committee on Cancer and the International
Union Against Cancer published staging protocols for epi-
thelial tumors arising from sinonasal complex. Of 29
articles published after 2003, 11 studies specifically used
the sixth or seventh edition of the TNM staging sys-
tem.24,29–31,35–37,41,42,44–46 The remaining articles did not
provide any information on the staging of treated adenocar-
cinomas except for 5 articles published before 2003, which
used an earlier version of these guidelines.13,15–19 All but a
few studies mentioned only the classification of the primary
tumor (see Table 2), only 8 articles reported N classification
at diagnosis, although these studies account for the larger
series.17,19,27,30,35,36,44,46 In total, we had T classification
information for 1221 patients. In 937N classification cases,
only 9N1 (1%), 3N2a (0.3%), 3N2b (0.3%), and 1N3
(0.1%) were recorded, the remaining 921 cases (98.3%)
were staged N0. Unfortunately, only 9 studies (364 patients)
reported hospital discharge times.7,9,21,26,33,40,42,44,46 The
available data showed a shorter hospitalization in the endo-
scopic surgery group (4.76 4.6 days) compared to the
endoscopic-assisted surgery and open approach groups
(9.26 3.7 and 11.56 4.9 days, respectively), which is statis-
tically significant (p< .01; Figure 3). Furthermore, 19 pub-
lished articles recorded perioperative and postoperative
complications comprising a total of 938
patients.13,15,21,23,24,26,27,29,31,33,36,39–46 The endoscopic sur-
gery and endoscopic-assisted surgery showed low rates of
major complications (6.6% and 25.9%, respectively) com-
pared with open approaches (36.4%; p< .01). Postoperative
deaths were recorded in 1 case of endoscopic-assisted sur-
gery and in 7 cases of open approaches, no postoperative
death was registered among patients who underwent endo-
scopic surgery (p5 .04). Minor complications occurred in
10% of the endoscopic surgery group and in 7.4% of the
open approach group, whereas these were recorded in 33.3%
of endoscopic-assisted surgery patients who underwent com-
bined endoscopic and open approach (Figure 4). In 9 studies,
adjuvant therapy was not documented or impossible to
deduce.9,13,14,21,22,25,31,34,37 According to T classification,
adjuvant radiotherapy (RT) was administered in 27.1% of T1
cases, 80% of T2 cases, 92.4% of T3 cases, 90.8% of T4a
cases, and 91% of T4b cases. In the endoscopic surgery
group, 78.9% of the cases received adjuvant RT, whereas the
endoscopic-assisted surgery and open approach patients had
adjuvant RT in 73.1% and 85.2%, respectively (p< .01).
FIGURE 2. Graphical display for quality assessment of diagnostic accuracy studies (QUADAS)-2 results.
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For what concerns the outcome and survival, statistics
varied among the articles, and, in some studies, data were
not amenable for meta-analysis.24,25,30–32,34 The mean
follow-up time was 51.96 45.8 months (range, 1–360
months), with 46.46 37.6 months (range, 2–180 months)
in the endoscopic surgery group and 53.66 47.6 months
(range, 1–360 months) in the open approach group
(p5 .09). Within the available data, 536 failure events
were reported: 424 local (31.5%), 15 regional (1.1%), and
97 distant (7.2%) failures, resulting in crude disease-free
survival (DFS) of 60.7% and local recurrence free sur-
vival of 67.6%. The crude DFS, locoregional relapse-free
survival, and overall survival (OS) according to T classifi-
cation between endoscopic surgery and open approach
groups is shown in Table 3. Univariate and multivariate
logistic regression analysis demonstrated that advanced T
classification and open approach are statistically related
to a high rate of major complications (odds ratio
[OR]5 6.1; p< .01 and OR5 3.5; p< .01, respectively).
Univariate and multivariate Cox regression model showed
that advanced T classification and open approach are stat-
istically related to the high rate of local relapses (see
Table 4). Regarding the OS, the univariate Cox regression
model highlighted the relationship among non-ITAC,
advanced T classification, and bad prognosis, albeit the
statistical significance persisted only for advanced T clas-
sification and open approach in a multivariate model (see
Table 5).
DISCUSSION
Endoscopic surgery is increasingly and effectively used
for sinonasal inflammatory diseases, even showing intra-
cranial extension, and benign tumors56; nevertheless, for
malignant tumors, this approach is in its relative infancy.
A comprehensive analysis of the existing evidence would
help to serve as a barometer for the state-of-the-art and to
suggest future directions. Given that different types of
tumors have several treatment survival implications
for patients, we focused this analysis on the surgical man-
agement of sinonasal adenocarcinomas comparing out-
comes between endoscopic surgery and traditional open
approaches. The potential benefits of endoscopic resec-
tions in sinonasal adenocarcinomas are numerous, includ-
ing lack of facial incisions, excellent visualization and
illumination of the surgical site, minimal trauma, shorter
hospital stay, and lower costs.57 However, any treatment
in sinonasal malignancies must be primarily judged by its
efficacy. In that respect, our study is not conclusive. This
is indeed a pooled analysis of patient data, rather than a
comparative meta-analysis. This is inevitable, as, up to
now, there are no comparative studies (and certainly no
randomized controlled trials) comparing endoscopic with
external approaches for adenocarcinomas.
The main problem in comparing different interventions
is Simpson’s paradox (ie, the effect of case mix); in our
case, the proportion of patients with T1/T2 versus T3/T4
tumors in the endoscopic versus the open approaches,
which could erroneously lead to false conclusions regard-
ing their efficacy.
It is true that smaller tumors are more likely to be
treated endoscopically, and this is indeed what we found
within our data. However, comparing results by T classi-
fication, we found that endoscopic management was asso-
ciated with better OS and DFS across almost all tumor
classifications.
FIGURE 3. Hospital stay according to the surgical techniques
(p< .01).
TABLE 2. Patients’ characteristics among surgical groups
Characteristics Endoscopic surgery Endoscopic-assisted surgery Open approaches p value
Male:female ratio 360:30 20:3 543:317 <.01
Age (mean6 SD) 64.36 13.3 59.76 12.4 61.16 12.8 <.01
ITAC:non-ITAC ratio 242:35 11:5 612:100 .11
No. of patients with wood dust exposure (%) 292 (67.8) 8 (25.8) 656 (51.7) <.01
No. of T1 (%) 52 (12.8) 1 (3.7) 56 (7.1) <.01
No. of T2 (%) 169 (41.4) 2 (7.4) 244 (31)
No. of T3 (%) 83 (20.3) 4 (14.8) 178 (22.7)
No. of T4a (%) 68 (16.7) 8 (29.6) 188 (23.9)
No. of T4b (%) 36 (8.8) 12 (44.4) 120 (15.3)
No. of N0 (%) 253 (98.8) 2 (100) 603 (98.4) .25
No. of N1 (%) 3 (1.2) 0 (0) 4 (0.7)
No. of N2a (%) 0 (0) 0 (0) 2 (0.3)
No. of N2b (%) 0 (0) 0 (0) 3 (0.5)
No. of N2c (%) 0 (0) 0 (0) 1 (0.2)
Abbreviation: ITAC, intestinal-type adenocarcinoma.
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An issue is the possible reporting bias. It is true that
the most experienced surgeons with the best results would
be the first to publish their results. Unfortunately, this is
true in all surgical series, and we can only acknowledge
it.
In our analysis, we found a statistically lower rate of
major and minor complications in endoscopic surgery
(16.6%) compared with open approaches (43.8%; p< .01).
Postoperative deaths were recorded only within patients
who underwent either endoscopic-assisted surgery or open
approach. Of note, the open craniectomy might represent a
risk factor in itself for the development of postoperative
complications; in fact, the higher rate of complications in
endoscopic-assisted surgery and open approach groups is
mainly related to this external approach. Furthermore, the
hospital stay in the endoscopic surgery group was statisti-
cally shorter compared with the endoscopic-assisted sur-
gery and open approach groups (p< .01). Almost all series
largely used postoperative RT in the majority of the cases,
and its use is reasonable in a district surrounded by noble
structures where wide clear margins are often difficult to
obtain7,10–12,15–20,23,24,26–30,32,33,35,36,39–46; nevertheless, no
randomized or even controlled trials of its precise role for
sinonasal adenocarcinomas are available. This does not
mean that RT plays no role in the management of sinonasal
adenocarcinomas, but highlights the importance of a com-
plete surgical resection. Outcomes are reported as com-
bined results with and without RT. Patients treated with
adjuvant RT are more likely to have locally advanced
tumors and to be high-grade and/or to have positive mar-
gins, and are not comparable with those treated with sur-
gery alone. Because of this understandable bias a
conclusion cannot be drawn on its precise role. The overall
local recurrence rate was reported as 32.5% with a rate of
17.8% for the endoscopic surgery group and 38.5% in the
open approach group. Nevertheless, a recurrence can occur
even 10 years or more after the initial treatment. The appli-
cation of endoscopic techniques for the management of
malignant sinonasal tumors is still controversial. The pri-
mary concern worries about the adherence to the oncologic
principle of en bloc excision with adequate margins. How-
ever, many sinonasal tumors have a small area of tissue
invasion despite filling the nasal cavity and paranasal
sinuses; furthermore, tumor growth into sinuses and skull
FIGURE 4. Distribution of complications.
TABLE 3. The crude survivals according to T classification
T classifications Endoscopic surgery group Open approach group p value
T1
DFS (no. of survivals) 81% (34) 80% (28) .57
Local recurrence-free survival (no. of survivals) 81% (34) 77.1% (27) .45
OS (no. of survivals) 81.3% (39) 76.4% (42) .36
T2
DFS (no. of survivals) 83.2% (134) 64.4% (139) <.01
Local recurrence-free survival (no. of survivals) 84.5% (136) 66.7% (144) <.01
OS (no. of survivals) 84.2% (139) 71.4% (162) <.01
T3
DFS (no. of survivals) 80.8% (63) 61% (94) <.01
Local recurrence-free survival (no. of survivals) 85.9% (67) 66.7% (102) <.01
OS (no. of survivals) 79.5% (62) 66.5% (111) .03
T4
DFS (no. of survivals) 70% (86) 41% (187) <.01
Local recurrence-free survival (no. of survivals) 77.2% (95) 57% (305) <.01
OS (no. of survivals) 66.4% (81) 47.1% (254) <.01
Abbreviations: DFS, disease-free survival; OS, overall survival.
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base regions often occurs by compression of bony struc-
tures rather than by direct invasion. En bloc excision of the
entire tumor is not necessary; instead, en bloc resection of
the area of invasion is performed with frozen section con-
trol confirming clear margins. In order to gain access to
the area of invasion, it is frequently necessary to debulk
the tumor first. Albeit this clearly violates the tumor, it
does not violate normal tissue planes surrounding the
malignant proliferation because the tumor is residing in an
air-filled cavity, and furthermore there is no evidence that
this intraoperative debulking increases the risk of local
recurrence. In fact, there are multiple examples of other
neoplasms that are removed in a piece-meal fashion with-
out jeopardizing the results: inverted papillomas, and laser
resection of laryngeal and pharyngeal carcinomas. Even
with an open surgical approach (craniofacial resection), en
bloc resection is not always possible because of the fragil-
ity and fragmentation of the specimen and the proximity to
vital structures. Thus, it is the final resection margin that is
crucial, and not the method of tumor removal.58 Neverthe-
less, there is no consensus regarding the indication and
contraindication for endoscopic surgery as treatment for
sinonasal adenocarcinomas. Some authors identified orbital
involvement as a contraindication,28,48 whereas others
argued that endoscopic surgery would still be an acceptable
method.27 Dural and intracranial extension, however,
served as a nearly universal contraindication to endoscopic
surgery,15,25,26 but this dogma has also been challenged
with the constant evolution of techniques, technology, and
surgeons expertise.44,46,59 Histopathologic typing is strictly
related to outcome with the poorly differentiated subtypes
faring worse. Thus, survival is better in papillary and colo-
nic (ITAC) type than in solid or mucinous type adenocarci-
nomas.60 Wood dust exposure as an etiologic factor that
confers a better prognosis in the larger, but not all,
series.30,35,36 As ITAC is a subtype of adenocarcinoma
showing histological features reminiscent of colonic adeno-
mas and adenocarcinomas, new therapeutic approaches,
such as targeted therapy with monoclonal antibodies
against epidermal growth factor receptor might, in the
future, be helpful in the therapeutic approach of these
lesions.61
The variability encountered in the reported data was
detailed in this study. This variability is partially indica-
tive of the rare nature of this tumor and the changes in
staging with time. Another aspect is the difficulty in the
interpretation of the oncologic results reported in some
studies, given that different histologies with different pat-
terns of behavior and prognosis where mixed. Further-
more, the staging information was not available in all
series, thus, this potential bias might distort the results of
this study. Nevertheless, for advanced T classifications,
surprisingly, the endoscopic surgery showed better out-
comes in survival than the traditional open approach.
CONCLUSION
Based on the available published data, endoscopic man-
agement of sinonasal adenocarcinomas seems to be a safe
and effective treatment modality. Recommendations for
future studies include the implementation of prospective
multi-institutional studies with detailed data regarding his-
tology, staging, surgical treatment, adjuvant treatment,
minor/major complications, and oncologic results.
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